Message #22 From:
NewsBot Date: December 4, 2006 06:03:00 AM
ISRY News IsoRay Announces Effectiveness of Registration Statement Relating to 9,064,890 Shares of Common Stock
RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (“IsoRay”)
(OTCBB:ISRY), a medical technology company focusing on innovative
treatment for prostate cancer and other solid cancer tumors through use
of its proprietary Cesium-131 brachytherapy seeds, announced that the
Securities and Exchange Commission will declare its Registration
Statement effective today at 5 p.m. (Eastern Time). Shareholders must
still comply with various state securities regulations to complete their
sales.
The Registration Statement relating to the resale of 9,064,890 shares of
common stock includes 4,233,950 shares of the Company’s
common stock issuable upon exercise of warrants. The Registration
Statement was required to comply with contractual obligations to
shareholders who acquired shares and warrants as part of the Company's
recent financing led by MicroCapital LLC. Under this Registration
Statement, the selling shareholders listed in the prospectus are
permitted, but are not obligated, to sell, from time to time, some or
all of their respective shares covered by the prospectus. IsoRay will
not receive any proceeds from the sale of shares under the Registration
Statement.
“This is an exciting milestone for the
company. With the effectiveness of this Registration Statement coupled
with the shares registered under our registration statement which became
effective on June 8, 2006, we have now approximately 13,701,880 shares
registered for our investors,” said IsoRay,
Inc. Chairman and CEO Roger Girard.
This communication shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
A copy of the prospectus is available on IsoRay’s
website at www.isoray.com
or on the Securities and Exchange Commission’s
website at www.sec.gov.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole
producer of the Cesium-131 brachytherapy seed, used to treat prostate
and other cancers. The Cesium-131 seed offers a significantly shorter
half-life than the two other isotopes commonly used for brachytherapy,
which results in a substantially faster delivery of therapeutic
radiation, lower probability of cancer cell survival and reduction of
the longevity of common brachytherapy side effects. IsoRay is based in
Richland, Washington. More information is available about IsoRay at www.isoray.com.
Forward-Looking Statement
This press release includes statements that may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements are
subject to a variety of known and unknown risks, uncertainties, and
other factors that are difficult to predict and many of which are beyond
management's control. Factors that can affect future results are
discussed in the documents filed by IsoRay from time to time with the
Securities and Exchange Commission. IsoRay undertakes no obligation to
update or revise any forward-looking statement to reflect new
information or events.
